TM
Thomas Miller
Co-Founder & CEO
California Institute of Technology
Thomas Miller is a theoretical chemist and Caltech professor who co-founded Iambic Therapeutics, bringing deep expertise in AI-driven molecular simulation to drug discovery.
Iambic Therapeutics is an AI-driven drug discovery company using deep learning and structure-based design to discover and develop small molecule therapeutics, with a primary focus on oncology.
Iambic Therapeutics is an AI-driven drug discovery company using deep learning and structure-based design to discover and develop small molecule therapeutics, with a primary focus on oncology.
Founded in 2021 by Thomas Miller (Caltech professor and theoretical chemist) and Fred Manby, Iambic emerged from academic research in AI and computational chemistry. The company is headquartered in San Diego, CA and has raised over $334M to advance its AI-discovered drug pipeline into clinical trials.
Iambic Therapeutics was highlighted as a top AI biotech company reshaping drug discovery in 2026, recognized for its deep-learning platform for structure-based design.
Iambic Therapeutics raised over $100M in an oversubscribed Series C round led by Sequoia Capital with participation from Regeneron and the Qatar Investment Authority, to advance AI-discovered cancer drugs into clinical trials.
Iambic Therapeutics progressed multiple AI-designed small molecule candidates targeting cancer into clinical development, marking a key milestone for AI-native drug discovery.
Iambic Therapeutics was recognized on CNBC's 2025 Disruptor 50 list, highlighting its pioneering use of AI for small molecule drug discovery in oncology.
Iambic Therapeutics entered into a strategic partnership with Takeda to leverage its AI platform for the discovery of novel small molecule therapeutics, reflecting pharma industry validation of AI-native drug discovery.
Iambic Therapeutics secured a $53M Series A round in July 2021 to build its AI-driven structure-based drug design platform and advance initial oncology programs.
Co-Founder & CEO
California Institute of Technology
Thomas Miller is a theoretical chemist and Caltech professor who co-founded Iambic Therapeutics, bringing deep expertise in AI-driven molecular simulation to drug discovery.
Co-Founder
University of Bristol
Fred Manby co-founded Iambic Therapeutics, contributing expertise in quantum chemistry and computational methods to the company's AI-driven drug discovery platform.
$253M raised total
No H1B sponsorship data available for this company.